Logo image of PRAX

PRAXIS PRECISION MEDICINES I (PRAX) Stock Fundamental Analysis

NASDAQ:PRAX - Nasdaq - US74006W2070 - Common Stock - Currency: USD

74.49  -5.05 (-6.35%)

After market: 74.49 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to PRAX. PRAX was compared to 572 industry peers in the Biotechnology industry. PRAX has a great financial health rating, but its profitability evaluates not so good. PRAX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRAX had negative earnings in the past year.
PRAX had a negative operating cash flow in the past year.
PRAX had negative earnings in each of the past 5 years.
In the past 5 years PRAX always reported negative operating cash flow.
PRAX Yearly Net Income VS EBIT VS OCF VS FCFPRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of PRAX (-36.28%) is better than 60.21% of its industry peers.
PRAX's Return On Equity of -39.46% is fine compared to the rest of the industry. PRAX outperforms 71.94% of its industry peers.
Industry RankSector Rank
ROA -36.28%
ROE -39.46%
ROIC N/A
ROA(3y)-127.73%
ROA(5y)-98.33%
ROE(3y)-174.93%
ROE(5y)-130.14%
ROIC(3y)N/A
ROIC(5y)N/A
PRAX Yearly ROA, ROE, ROICPRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

PRAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRAX Yearly Profit, Operating, Gross MarginsPRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

9

2. Health

2.1 Basic Checks

PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRAX has less shares outstanding
Compared to 5 years ago, PRAX has less shares outstanding
PRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRAX Yearly Shares OutstandingPRAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
PRAX Yearly Total Debt VS Total AssetsPRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 23.51 indicates that PRAX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 23.51, PRAX belongs to the best of the industry, outperforming 94.49% of the companies in the same industry.
PRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.51
ROIC/WACCN/A
WACC9.44%
PRAX Yearly LT Debt VS Equity VS FCFPRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.96 indicates that PRAX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.96, PRAX belongs to the best of the industry, outperforming 82.42% of the companies in the same industry.
A Quick Ratio of 10.96 indicates that PRAX has no problem at all paying its short term obligations.
PRAX's Quick ratio of 10.96 is amongst the best of the industry. PRAX outperforms 82.42% of its industry peers.
Industry RankSector Rank
Current Ratio 10.96
Quick Ratio 10.96
PRAX Yearly Current Assets VS Current LiabilitesPRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 69.48% over the past year.
Looking at the last year, PRAX shows a very negative growth in Revenue. The Revenue has decreased by -16.93% in the last year.
EPS 1Y (TTM)69.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.85%
Revenue 1Y (TTM)-16.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-35.47%

3.2 Future

Based on estimates for the next years, PRAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.80% on average per year.
Based on estimates for the next years, PRAX will show a very strong growth in Revenue. The Revenue will grow by 178.99% on average per year.
EPS Next Y56.47%
EPS Next 2Y22.31%
EPS Next 3Y14.29%
EPS Next 5Y13.8%
Revenue Next Year-26.01%
Revenue Next 2Y-30.66%
Revenue Next 3Y153.15%
Revenue Next 5Y178.99%

3.3 Evolution

PRAX Yearly Revenue VS EstimatesPRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
PRAX Yearly EPS VS EstimatesPRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRAX Price Earnings VS Forward Price EarningsPRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRAX Per share dataPRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

PRAX's earnings are expected to grow with 14.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.31%
EPS Next 3Y14.29%

More info and screens

0

5. Dividend

5.1 Amount

PRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRAXIS PRECISION MEDICINES I

NASDAQ:PRAX (2/21/2025, 8:00:01 PM)

After market: 74.49 0 (0%)

74.49

-5.05 (-6.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)03-03 2025-03-03/amc
Inst Owners100.83%
Inst Owner Change13.51%
Ins Owners0.3%
Ins Owner Change1.91%
Market Cap1.39B
Analysts85
Price Target168.81 (126.62%)
Short Float %15.17%
Short Ratio7.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.62%
Min EPS beat(2)-35.55%
Max EPS beat(2)26.31%
EPS beat(4)2
Avg EPS beat(4)-8.58%
Min EPS beat(4)-35.55%
Max EPS beat(4)26.31%
EPS beat(8)5
Avg EPS beat(8)5.59%
EPS beat(12)6
Avg EPS beat(12)0.63%
EPS beat(16)7
Avg EPS beat(16)-9.15%
Revenue beat(2)1
Avg Revenue beat(2)-28.98%
Min Revenue beat(2)-57.98%
Max Revenue beat(2)0.03%
Revenue beat(4)2
Avg Revenue beat(4)194.48%
Min Revenue beat(4)-73.94%
Max Revenue beat(4)909.8%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.78%
PT rev (3m)13.01%
EPS NQ rev (1m)0.2%
EPS NQ rev (3m)-27.26%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-13.49%
Revenue NQ rev (1m)-1.62%
Revenue NQ rev (3m)-3.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 865.11
P/FCF N/A
P/OCF N/A
P/B 3.63
P/tB 3.63
EV/EBITDA N/A
EPS(TTM)-10.3
EYN/A
EPS(NY)-11.93
Fwd EYN/A
FCF(TTM)-5.34
FCFYN/A
OCF(TTM)-5.34
OCFYN/A
SpS0.09
BVpS20.53
TBVpS20.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.28%
ROE -39.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-127.73%
ROA(5y)-98.33%
ROE(3y)-174.93%
ROE(5y)-130.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.96
Quick Ratio 10.96
Altman-Z 23.51
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)233.22%
Cap/Depr(5y)189.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.85%
EPS Next Y56.47%
EPS Next 2Y22.31%
EPS Next 3Y14.29%
EPS Next 5Y13.8%
Revenue 1Y (TTM)-16.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-35.47%
Revenue Next Year-26.01%
Revenue Next 2Y-30.66%
Revenue Next 3Y153.15%
Revenue Next 5Y178.99%
EBIT growth 1Y-17.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.94%
EBIT Next 3Y-31.08%
EBIT Next 5Y-1.11%
FCF growth 1Y50.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.52%
OCF growth 3YN/A
OCF growth 5YN/A